COMPANY

Aeovian Pharmaceuticals

Keywords: neurology Tuberous Sclerosis Complex Epilepsy AV078

Location: Berkeley, CA · source · Oct 15, 2026

Profile checked Oct 10, 2026

Funding and NIH signals

SEC Form D raise Raised $55M (Form D filed Dec 22, 2025). SEC Form D 0000905148-25-004456 (Dec 22, 2025)
Evidence (1 event)
- Dec 22, 2025 · SEC Form D 0000905148-25-004456
  Name of Issuer: Aeovian Pharmaceuticals, Inc.; CIK: 1710088; Address: Berkeley, CA; Submission type: D; Filing date: 2025-12-22; Industry Group: Pharmaceuticals; Date of First Sale: 2025-11-18; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 54999996; Total Amount Sold: 54999996; Federal exemptions: 06b

Job counts as of Oct 18, 2026. All funding and NIH signals

Sep 1, 2026 Trial start Phase 2: Safety and Efficacy of AV078 in Participants With Tuberous Sclerosis Complex (TSC) Refractory Epilepsy (RESTOR-1) source ↗
Jan 31, 2024 Trial start Phase 1: Assessment of the Safety, Tolerability and Pharmacokinetics of AV078 in Healthy Volunteers source ↗

Sep 1, 2027 (ESTIMATED) · Phase 2 · Safety and Efficacy of AV078 in Participants With Tuberous Sclerosis Complex (TSC) Refractory Epilepsy (RESTOR-1) · NCT07680322

Estimated primary completion per ClinicalTrials.gov. Dates move.

Record	Title	Phase	Status	Start	Primary completion
NCT07680322	Safety and Efficacy of AV078 in Participants With Tuberous Sclerosis Complex (TSC) Refractory Epilepsy (RESTOR-1)	Phase 2	Not yet recruiting	Sep 1, 2026	Sep 1, 2027 (estimated)
NCT06205381	Assessment of the Safety, Tolerability and Pharmacokinetics of AV078 in Healthy Volunteers	Phase 1	Completed	Jan 31, 2024	Feb 8, 2025 (actual)

Form D raises come from the company’s own SEC filing (last 2 years).

InvestorListed in the portfolio of Sofinnova Investments (captured Oct 12, 2026). portfolio page ↗